In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

In a report released today, Myles Minter from William Blair reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report). The ...

Equities research analysts at William Blair lifted their Q1 2025 earnings estimates for HealthStream in a research note issued on Tuesday, February 25th. William Blair analyst R. Daniels now forecasts ...

William Blair International Growth Fund earns an Average Process Pillar rating. The main driver of the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ...

Investing.com -- William Blair downgraded Tempus AI Inc (NASDAQ:TEM) to "Market Perform" from "Outperform" given stock's sharp rally rather than any concerns over the company’s fundamentals. Tempus ...

Analysts at William Blair upped their FY2025 EPS estimates for Straumann in a report issued on Monday, February 24th. William Blair analyst B. Vazquez now forecasts that the company will post earnings ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process is strengthened by low costs across its parent firm's funds, whose fees rank in their respective ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The Fund seeks long-term capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of equity securities, including common ...